Accelerating Medicines for Parkinson's Disease Webinar

December 05, 2019

Contact: Debra Babcock, M.D., Ph.D.
Contact Number: (301) 496-9964
Contact Email:

Webinar: December 5, 2019, 1 - 5 p.m. EST

AMP PD logo

The Accelerating Medicines Partnership (AMP) is a public-private partnership between the National Institutes of Health (NIH), multiple biopharmaceutical and life sciences companies, and non-profit organizations. Managed through the Foundation for the NIH (FNIH), AMP aims to identify and validate the most promising biological targets for therapeutics. In 2016, the AMP Executive Committee approved the planning of an AMP effort to confront the challenges presented by Parkinson’s disease (PD). This complements current efforts in the areas of Alzheimer’s disease, type 2 diabetes, and the autoimmune disorders of rheumatoid arthritis and systemic lupus erythematosus (lupus). A critical component of this partnership is that all members have agreed to make the AMP Parkinson’s disease (AMP PD) data and analyses publicly available to the broad biomedical community. 

The success of clinical trials aimed at developing new treatments for PD hinges on identifying and validating biomarkers that can track the progression of the disease. A wealth of information has been collected from individuals with PD through such programs as the NINDS’s Parkinson’s Disease Biomarkers Program (PDBP), The Michael J. Fox Foundation (MJFF)’s Parkinson’s Progression Markers Initiative, the MJFF/NINDS BioFIND cohort and the Harvard Biomarkers Study. However, the resources, time, and cost required to perform a large-scale analysis of that data has been prohibitive for individual researchers, companies and organizations.  AMP PD provides the expertise and support needed to determine which biomarkers show the greatest potential for predicting PD and the progression of the disease.

Industry partner Verily (an Alphabet company) has created a platform called the AMP PD Knowledge Portal to house clinical, transcriptomics, and whole genome sequencing data  from more than 3,000 PD cases and more than 1,700 healthy controls. This data and analyses will be made available across the entire partnership and to the broader research community.

AMP PD Partners


  • NIH (NINDS and NIA)
  • FDA


  • Celgene
  • Foundation for the NIH
  • GlaxoSmithKline
  • Michael J. Fox Foundation
  • Pfizer
  • Sanofi
  • Verily

Related Resources

Was this page helpful?
Form Approved OMB# 0925-0648 Exp. Date 06/2024